What changed: Atypical teratoid/rhabdoid tumour (ATRT)
Every dated change on the records linked to Atypical teratoid/rhabdoid tumour (ATRT), newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
September 2026 · 1
2022 · 1
2020 · 3
- 2020GuidelineAtypical teratoid/rhabdoid tumour (ATRT)Guideline COG ACNS0333 (JCO 2020); EU-RHAB: Newly diagnosed, any age
Maximal safe resection followed by an intensive multimodal protocol: ACNS0333-style induction, high-dose chemotherapy with autologous stem-cell rescue, and age-adapted focal radiotherapy; or the EU-RHAB regimen with intraventricular methotrexate. Enrolment in SIOPE ATRT01 or a COG successor where available.
- 2020MilestoneAutologous stem cell transplant (high-dose therapy)ACNS0333 reports improved survival with intensive therapy
COG phase 3 with high-dose chemotherapy and autologous rescue (JCO 2020).
- 2020MilestoneTazemetostatTazemetostat approved for SMARCB1-negative epithelioid sarcoma
First EZH2 inhibitor approval; paediatric rhabdoid tumour responses in the phase 1 programme.